- Home
- BRX vs JAZZ Comparison
BRX vs JAZZ Comparison
Compare BRX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRX | JAZZ |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.4B |
| IPO Year | 2013 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BRX | JAZZ |
|---|---|---|
| Price | $30.45 | $189.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $30.27 | ★ $211.25 |
| AVG Volume (30 Days) | ★ 3.1M | 920.6K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | $1,371,597,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $5.50 | $7.60 |
| Revenue Next Year | $4.01 | $8.34 |
| P/E Ratio | $24.08 | ★ N/A |
| Revenue Growth | ★ 6.73 | N/A |
| 52 Week Low | $23.84 | $95.49 |
| 52 Week High | $30.11 | $197.47 |
Technical Indicators
Market Signals| Indicator | BRX | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 78.27 | 70.66 |
| Support Level | $25.49 | $159.78 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.46 | 5.04 |
| MACD | 0.11 | 2.69 |
| Stochastic Oscillator | 99.42 | 75.97 |
Price Performance
Historical ComparisonAbout BRX Brixmor Property Group Inc.
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.